Dual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in Advanced Alveolar Soft Part Sarcoma: A Single-Center, Phase II Trial
- 13 August 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (21) , 4800-4806
Abstract
Purpose: Alveolar soft part sarcoma (ASPS) is an ultrarare soft tissue sarcoma. Current standard therapy with PD-1/PD-L1 inhibitors achieves limited response rates (<40%). Lymphocyte-activation gene 3 (LAG-3) is coexpressed with PD-1 on exhausted T cells, and dual blockade has shown synergy in some solid tumors but remains unexplored in sarcoma. This trial evaluated the efficacy of IBI110 (anti–LAG-3) plus sintilimab (anti–PD-1) in advanced ASPS. Patients and Methods: This open-label, phase II study enrolled 28 patients from July 2022 to September 2023 (median follow-up, 33.6 months). Both drugs were given intravenously at 200 mg every 3 weeks. The primary endpoint was overall response rate (ORR) by RECIST v1.1. Results: Among 28 patients, 8 (28.6%) were resistant to prior immune checkpoint inhibitors (ICI), and 20 (71.4%) were ICI-naïve. The overall ORR was 51.8% (14/27 evaluable), including 4 complete responses and 10 partial responses. During a median follow-up of 33.6 months, the median progression-free survival (PFS) and overall survival (OS) were not reached in the whole population. In ICI-naïve patients, the ORR was 60%, with median PFS/OS not reached. In ICI-resistant patients, the ORR was 25%, with median PFS of 14.9 months and median OS of 25.4 months. The median time to response was 3.3 months; the median duration of response (DoR) was not reached. Grade 3 to 4 treatment-related adverse events occurred in nine patients (32.1%), with no treatment-related deaths. Exploratory analysis showed that responders had significantly higher baseline LAG-3+ cell density in tumor specimens. Conclusions: Dual LAG-3/PD-1 blockade demonstrated promising and durable antitumor activity with manageable safety in both ICI-naïve and ICI-resistant advanced ASPS, warranting further investigation.Keywords
All Related Versions
Funding Information
- Chinese Academy of Medical Sciences Innnovation Fund for Medical Sciences (2024-I2M-TS-031)
- Chinese Academy of Medical Sciences Innnovation Fund for Medical Sciences (2024-I2M-TS-047)
- Chinese Academy of Medical Sciences Innnovation Fund for Medical Sciences (2023-I2M-2-010)
- Chinese Academy of Medical Sciences Innnovation Fund for Medical Sciences (2022-I2M-2-004)
- National Natural Science Foundation of China (82572111)
- National Natural Science Foundation of China (82503984)
- National Natural Science Foundation of Beijing Municipality (L258037)
This publication has 31 references indexed in Scilit:
- LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunityCell, 2024
- Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunityCell, 2024
- LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicityCell, 2024
- Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510)Cancer, 2024
- Immune checkpoint therapy—current perspectives and future directionsCell, 2023
- Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entitiesCancer, 2021
- Characterization of alveolar soft part sarcoma using a large national databaseSurgery, 2020
- Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part SarcomaJAMA Oncology, 2019
- LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating LymphocytesJournal of Thoracic Oncology, 2017
- Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adultsJournal of Pediatric Surgery, 2006